You are here

Novel approach for rapid generation of human antibodies to RNA-modifications

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DA042461-01
Agency Tracking Number: R43DA042461
Amount: $224,638.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDA
Solicitation Number: DA16-005
Solicitation Year: 2016
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-07-01
Award End Date (Contract End Date): 2018-06-30
Small Business Information
Pottstown, PA 19464-3468
United States
DUNS: 962964990
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (610) 931-7547
Business Contact
Phone: (610) 990-7531
Research Institution

Project Summary It is known that protein activity can be modulated by post translational protein
phosphorylation Phospho specific antibodies have greatly advanced understanding of the mechanisms of
protein activation and signaling in cellular pathways Post transcriptional RNA modification is more
complicated as there are known RNA modifications that occur in thousands of RNAs in eukaryotic cells A
number of these RNA modifications have been shown to influence the development and physiology of the
central nervous system CNS The availability of antibodies against RNA modifications at specific RNA
sequences analogous to phospho specific antibodies will facilitate investigation of the relationships between
specific RNA modifications and their cellular function Unfortunately due to in vivo instability of RNAs and their
non immunogenicity it is difficult to raise antibodies against RNA modifications in animals The goal of this
project is to develop an in vitro novel platform for rapid generation and robust production of a set of antibodies
against specific RNA modifications As proof of principle in Phase I a yeast based self diversifying library of
human single chain variable fragment ScFv will be established and ScFv antibodies capable of recognizing
Inosine I methylcytosine m C N methyladenosine m A nucleosides and mRNA containing Adenine
to Inosine A to I modification at the site A of mouse C receptor will be developed In phase II the effort will
be dedicated to develop antibodies capable of recognizing RNA modification at a given RNA context such as
A to I modification of A B C D and E sites of mouse C receptor mRNA as well as A to I modifications found
in other mRNA such as GluR and KA receptors In addition the developed platform will be used for
generating antibodies to other RNA modifications Availability of such reagents will enable researchers to
monitor the effect of specific RNA modification on the structure or function of respective individual RNA or to
analyze tissue sections e g tumor samples for the occurrence of such modifications Narrative As a result of this proposed project a novel antibody discovery platform will be established and a
set of antibodies capable of detecting various RNA modifications will be developed These antibodies enable
detection quantitation or immunoprecipitation of modified RNAs

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government